|Bid||60.95 x 900|
|Ask||61.09 x 1000|
|Day's Range||58.86 - 62.44|
|52 Week Range||6.16 - 63.78|
|Beta (5Y Monthly)||2.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2020 - Aug 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.67|
Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10 billion are also found in the small cap universe. Small cap stocks, as represented by the Russell 2000 Index (RUT), have underperformed the broader market over the past 12 months.
ChemoCentryx, Inc., (CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from a forty-six (46) patient Phase II dose-ranging trial in the orphan kidney disorder, primary Focal Segmental Glomerulosclerosis (FSGS). The LUMINA-1 trial tested CCX140, an orally-administered selective inhibitor of the chemokine receptor known as CCR2, in primary FSGS subjects. In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.
Market forces rained on the parade of ChemoCentryx, Inc. (NASDAQ:CCXI) shareholders today, when the analysts...
It's shaping up to be a tough period for ChemoCentryx, Inc. (NASDAQ:CCXI), which a week ago released some...
Joining me on the call today is Dr. Thomas Schall, President and Chief Executive Officer of ChemoCentryx, who will review the company's recent business and clinical progress. Following his comments, Susan Kanaya, Executive Vice President, Chief Financial and Administrative Officer of ChemoCentryx, will provide an overview of the company's financial highlights for the first quarter 2020 before turning the call back over to Tom for closing remarks.
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -16.67% and -32.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
ChemoCentryx, Inc., (CCXI), today announced financial results for the first quarter ended March 31, 2020 and provided an overview of the Company's recent corporate highlights. "In the face of this global infection pandemic, we pause in sympathy for those suffering while we are reminded of the deep importance of our mission,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.
Today we will run through one way of estimating the intrinsic value of ChemoCentryx, Inc. (NASDAQ:CCXI) by estimating...
ChemoCentryx, Inc., (CCXI), today announced that the Company's first quarter 2020 financial results will be released after market close on Monday, May 11, 2020. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on May 11, 2020 to discuss these results and to answer questions. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com.
ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx (CCXI) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
There's been a notable change in appetite for ChemoCentryx, Inc. (NASDAQ:CCXI) shares in the week since its full-year...
ChemoCentryx (CCXI) delivered earnings and revenue surprises of 3.70% and 6.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
-- Announced positive topline data from pivotal Phase III ADVOCATE trial for ANCA-vasculitis in Q4; U.S. NDA filing expected mid-2020 -- -- “2020 4-Sight” on the horizon with.
NEW YORK, NY / ACCESSWIRE / March 10, 2020 / ChemoCentryx, Inc. (NASDAQ:CCXI) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 10, 2020 at 5:00 PM ...
MOUNTAIN VIEW, Calif., March 03, 2020 -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2019 financial results will be.
ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ChemoCentryx, Inc., (CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 9th Annual SVB Leerink Healthcare Conference on Wednesday, February 26, 2020 at 3:00 p.m. ET. The conference will be held at the Lotte New York Palace in New York, NY. A live audio webcast of the presentations can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com.
Life sciences companies like to release a flurry of news in the days ahead of the giant J.P. Morgan Healthcare Conference in San Francisco to create fresh nuggets for potential investors and partners to gnaw on. Yet too much noise sometimes can hurt their message.
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...